Introduction {#S0001}
============

Physical activity has been shown to have several health benefits such as reducing the risk of ischemic heart disease, diabetes and colon cancer \[[1](#CIT0001)\]. Most of the previous research on physical activity has focused on moderate to vigorous intensity activities such as running whereas less is known on the low intensity everyday movement which constitutes the majority of the physical activity accumulated throughout the day. A structured exercise program is often used as an intervention in studies, but the rest of the daily physical activity is frequently overlooked. Caspersen et al. \[[2](#CIT0002)\] defined physical activity as 'any bodily movement produced by skeletal muscles that requires energy expenditure' and physical exercise as 'a subset of physical activity that is planned, structured, and repetitive and has as a final or an intermediate objective the improvement or maintenance of physical fitness'. These definitions are currently used by the World Health Organization (WHO) \[[3](#CIT0003)\]. Physical activity thus includes all human movement whereas physical exercise is high or moderate intensity movement conducted with a purpose for shorter periods of time. It is important to differentiate between these two terms since different intensities of physical activity have different effects on the body \[[4](#CIT0004)\]. Thus, it is crucial to study physical activity as a whole instead of focusing solely on the moderate to vigorous intensity activities. In the context of this study the term physical activity includes all physical activities from lounging around the shopping mall to going for a jog and the term exercise only means moderate to high intensity activities.

Asthma is a chronic inflammatory disease of the airways. Over the past years researchers have identified several phenotypes of asthma revealing the heterogeneity of the disease \[[5](#CIT0005),[6](#CIT0006)\]. Age of onset of asthma has been found as a key differentiating factor between the phenotypes. It has been shown recently that the adult-onset phenotypes differ vastly from childhood-onset asthma \[[5](#CIT0005),[6](#CIT0006)\]. Childhood asthma is often an atopic disease characterized by high numbers of bronchial eosinophils and high serum levels of IgE with a good response to glucocorticoid treatment. In contrast, patients with disease onset at adulthood have often more severe asthma that rarely remits \[[7](#CIT0007)\]. Recently, asthma diagnosed at adult-age has been shown to constitute a majority among all new cases of asthma \[[8](#CIT0008)\], and it seems that several lifestyle factors such as cigarette smoking and obesity are major factors in adult-onset asthma \[[6](#CIT0006),[9](#CIT0009)\]. Since the concept of adult-onset phenotypes is rather new, only few studies exist on it and there is no clear consensus on the best therapy for these patients. Occasionally, adult-onset asthma may also be difficult to distinguish from chronic obstructive pulmonary disease (COPD) due to the overlap of symptoms and risk factors \[[10](#CIT0010)\].

Physical exercise has been shown to be a beneficial factor in the control of asthma \[[11](#CIT0011)\]. Physical exercise reduces systemic and bronchial inflammation, and increases maximal oxygen uptake \[[12](#CIT0012),[13](#CIT0013)\]. Most research on daily physical activity in asthma focuses either on the risk of developing asthma or exercise-induced bronchoconstriction. There are no published long-term studies on daily physical activity in patients with clinical asthma. Daily physical activity has been studied extensively in COPD where higher levels of physical activity decelerate lung function decline and improve the quality of life \[[14](#CIT0014),[15](#CIT0015)\]. Previous reports have shown that high physical activity is associated with better lung function, slower lung function decline, and lower mortality also in the general population \[[16](#CIT0016),[17](#CIT0017)\]. However, so far there are no previous studies on the association between physical activity and lung function change over several years in patients with clinical asthma.

The aim of this study was to examine the association between daily physical activity and asthma control, lung function, or lung function decline in patients with adult-onset asthma.

Materials and methods {#S0002}
=====================

Study population and design {#S0002-S2001}
---------------------------

Seinäjoki Adult Asthma Study (SAAS) is a single-center (Department of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland) 12-year follow-up study. The study protocol and the inclusion and exclusion criteria have been previously published \[[18](#CIT0018)\]. Study population consists of 260 consecutive patients who were diagnosed with adult-onset asthma in 1999--2002 by a respiratory physician ([Figure 1](#F0001)). Patients were recruited from the diagnostic visit. Diagnosis was based on typical symptoms, and it was confirmed by objective lung function measurements \[[18](#CIT0018)\]. Smokers (current or ex-) and patients with co-morbidities were included in the study. The patients were treated and monitored according to Finnish Asthma Program guidelines \[[19](#CIT0019)\] either in the specialized care or in primary care. The collection of research data has been previously reported \[[7](#CIT0007),[9](#CIT0009),[10](#CIT0010),[20](#CIT0020)\]. At diagnosis, data was collected on lung function, blood eosinophils, the initial pharmacotherapy, and asthma symptoms by Airways Questionnaire 20 (AQ20) \[[21](#CIT0021)\]. Atopy was defined as at least one positive response (≥3 mm) in skin prick toward common aeroallergens. After 12 years patients were invited to a re-evaluation (2012--2013), and 201 (77%) patients arrived to the follow-up visit. At follow-up information was collected on asthma status, medication, and co-morbidities by structured questionnaire. Lung function, blood eosinophils and neutrophils, IgE levels, fraction of exhaled nitric oxide (FeNO), interleukin-6 (IL-6), and high sensitivity C-reactive protein (hsCRP) were measured. Patients also filled Asthma Control Test (ACT) \[[22](#CIT0022)\], AQ20, and a structured lifestyle questionnaire. Specifically trained research nurse reviewed all questionnaires with the patients to limit misunderstandings. A written informed consent was obtained to a study protocol approved by the Ethics committee of Tampere University Hospital, Tampere, Finland (R12122).10.1080/20018525.2018.1533753-F0001Figure 1.Flow chart of the study.

Determination of physical activity {#S0002-S2002}
----------------------------------

The level of physical activity was assessed at follow-up by a structured questionnaire. Overall daily physical activity was assessed by an open question: 'How many minutes in a day do you spend moving?' After pre-evaluation, patients were divided into high and low daily physical activity groups. Cut off-point was established at 240 min of daily physical activity per day. The frequency of physical exercise was estimated by the following question: 'How often do you take part in leisure time activities for at least half an hour so that you are at least somewhat breathless and sweaty?' This question had eight choices ranging from never to everyday. In this study, physical activity time and physical exercise frequency are assessed as their own variables and are not to be confused with each other.

Determination of lung function {#S0002-S2003}
------------------------------

Lung function was assessed using a spirometer (Vmax Encore 22, Viasys Healthcare, Palm Springs, CA, USA) according to international recommendations \[[23](#CIT0023)\] and Finnish reference values \[[24](#CIT0024)\]. Post-bronchodilator measurements were taken 15 min after inhalation of salbutamol (400 µg). After the initiation of asthma therapy, only pre-bronchodilator spirometry was measured on most of the patients, and therefore we evaluated the changes in pre-bronchodilator spirometry values throughout the study. Lung function measurement points were: (1) baseline (i.e. time of asthma diagnosis), (2) the maximum lung function (Max~0-2.5~) during the first 2.5 years after diagnosis (i.e. after start of anti-inflammatory therapy) based on the highest pre-bronchodilator FEV~1~% predicted, and (3) after 12 years of follow-up ([Figure 2](#F0002)) \[[9](#CIT0009)\].10.1080/20018525.2018.1533753-F0002Figure 2.Representation of the three lung function measurement points.

Statistical analyses {#S0002-S2004}
--------------------

Continuous data is expressed as mean (SD) for variables with normal distribution and as median and interquartile range for variables with skewed distribution. To assess differences between high and low physical activity groups, we used Mann-Whitney test for continuous variables with skewed distributions, independent samples t-test for continuous variables with normal distribution, and Chi-Square test for categorized variables.

Multiple linear regression analysis was performed to analyze factors associated with FEV~1~ decline from point of Max~0-2.5~ to the follow-up visit. To avoid multicollinearity, explanatory variables were checked for strong (\>0.7) mutual correlation. Patients whose BMI differed over 3 SD (*n* = 4) or whose FEV~1~ decline differed over 3.3 SD (*n* = 3) from mean were removed from the linear regression analysis as outliers to ensure homoscedasticity. Forward, backward and enter methods were used to improve model fit. Statistical analyses were performed using SPSS software, version 23 (IBM SPSS, Chicago, IL, USA). A *p*-value \<0.05 was regarded as statistically significant.

Results {#S0003}
=======

Patient characteristics {#S0003-S2001}
-----------------------

Characteristics of the patients who attended the follow-up visit are shown at eTable 1. The median age of the study population was 45 (SD 14) years at diagnosis and 58% were females. Of the patients, 53% had smoking history. The proportion of daily inhaled glucocorticoid users was 8% at diagnosis, 96% at Max~0-2.5~, and 76% at follow-up. Patients reported a median of 360 (interquartile range 180--540) min of daily physical activity.

When patients were divided into two groups based on the level of daily physical activity (≤240 min vs. \>240 min) the group with the higher amount of physical activity was younger and they had earlier asthma-onset ([Table 1](#T0001)). The high physical activity group included a higher percentage of females than the low physical activity group. The high physical activity group also included less patients with post-bronchodilator FEV~1~/FVC\<0.7 and a history of smoking for at least 10 pack years ([Table 1](#T0001)), characteristics which may indicate an asthma-COPD overlap syndrome (ACOS) \[[25](#CIT0025)\]. Notably, there were no differences in BMI, smoking status, medication for asthma, or frequency of physical exercise between the two groups ([Table 1](#T0001)).10.1080/20018525.2018.1533753-T0001Table 1.Basic subject characteristics by physical activity groups. ≤240 min of physical activity/day\>240 min of physical activity/day*p*-value\*Number of patients74127 Age (years)61 (13)57 (14)**0.036**Age of onset (years)49 (13)44 (14)**0.029**Males39 (53%)45 (35%)**0.018**Duration of daily physical activity (min)135 (90--180)480 (360--600)**\<0.001**Patients exercising at least 3 times per week43 (58%)69 (54%)0.660BMI (kg/m^2^)28.7 (5.2)28.4 (5.8)0.807Ex or current smoker38 (51%)68 (54%)0.772Pack years (of ex- and current smokers)20 (10--32)15 (4--27)0.067Post-brochodilator FEV~1~/FVC \<0.7 and at least 10 pack years17 (24%)16 (13%)**0.050**Patients with at least one co-morbidity51 (70%)76 (60%)0.172Number of co-morbidities, COPD included1 (0--3)1 (0--2)0.091Daily ICS users60 (81%)93 (73%)0.233ICS dose (μg budesonide equivalent)800 (400--1000)800 (280--1000)0.393Patients who received oral corticosteroids30 (41%)35 (28%)0.062Daily add-on medication (includes LABA)39 (53%)62 (49%)0.661Atopy18 (27%)49 (42%)0.055[^2]

Association between physical activity and lung function {#S0003-S2002}
-------------------------------------------------------

Lung function was significantly different between the high and low physical activity groups. The high physical activity group had higher pre- and post-bronchodilator FEV~1~-values at follow-up ([Table 2](#T0002)) but only pre-bronchodilator FEV~1~-value was higher at diagnosis (eTable 2). FEV~1~/FVC-ratios (pre- and post-BD) were significantly different at diagnosis and at follow-up between the groups ([Table 2](#T0002), eTable 2). After removal of patients with post-bronchodilator FEV~1~/FVC\<0.7 and a smoking history of at least 10 pack years (eTable 3), which may indicate the presence of ACOS \[[25](#CIT0025)\], post-bronchodilator FEV~1~/FVC-ratio at follow-up remained significantly lower in the low activity group (*p* = 0.032). This indicates that possible ACOS is not explaining the results.10.1080/20018525.2018.1533753-T0002Table 2.Lung function at follow-up by physical activity groups. ≤240 min of physical activity/day\>240 min of physical activity/day*p*-value\*FVC (%ref) pre-BD95 (16)98 (15)0,222FVC (%ref) post-BD97 (16)99 (14)0,269FEV1 (%ref) pre-BD81 (19)88 (16)**0,004**FEV1 (%ref) post-BD84 (18)91 (16)**0,004**FEV1/FVC pre-BD0.71 (0.63--0.78)0.75 (0.69--0.79)**0,002**FEV1/FVC post-BD0.72 (0.65--0.79)0.77 (0.71--0.81)**0,001**[^3]

Association between physical activity and lung function decline {#S0003-S2003}
---------------------------------------------------------------

When evaluating lung function decline from Max~0-2.5~ to follow-up visit in the high and low physical activity groups, a more rapid decline in FEV~1~ (ml and % of reference) and FVC (ml) in the group with less daily physical activity was observed ([Table 3](#T0003), [Figure 3](#F0003)). The measurement point of Max~0-2.5~ was chosen because the patients had untreated asthma at diagnosis, and their lung function improved significantly during the following months due to start of asthma therapy. Therefore, comparisons between diagnostic and follow-up values would be comparisons between untreated and treated asthma. The differences between the groups remained significant when patients with post-bronchodilator FEV~1~/FVC\<0.7 and a smoking history of at least 10 pack years were removed from the cohort (eTable 4). The frequency of physical exercise had no effect on lung function decline (data not shown).10.1080/20018525.2018.1533753-T0003Table 3.Annual pre-BD lung function decline from Max~0-2.5~ to follow-up by physical activity group. ≤240 min of physical activity/day\>240 min of physical activity/day*p*-value\*ΔFVC/year, pre-BD (ml)−43.6 (42.1)−29.3 (39.7)**0.018**ΔFVC/year, pre-BD (%)−0.12 (1.14)0.03 (0.95)0.325ΔFEV1/year, pre-BD (ml)−58.8 (37.3)−41.4 (34.2)**0.001**ΔFEV1/year, pre-BD (%)−0.83 (1.13)−0.39 (0.97)**0.005**ΔFEV1/ΔFVC -ratio/year, pre-BD−0.0052 (−0.0101 to −0.0019)−0.0041 (−0.0075 to −0.0016)0.062[^4] 10.1080/20018525.2018.1533753-F0003Figure 3.Changes in mean Pre-BD FEV~1~ (mL) during 12 years of follow-up in the groups of \<240 or ≥240 min of daily physical activity.

Association between daily physical activity, asthma control, and symptoms of asthma {#S0003-S2004}
-----------------------------------------------------------------------------------

The high and low physical activity groups had no significant difference in asthma control or symptoms when measured by using AQ20 overall scores (eTable 5) or ACT ([Table 4](#T0004)). However, when analyzing the separate questions in ACT and AQ20 questionnaires, differences were found. The low physical activity group had more shortness of breath and a worse self-perceived asthma control (ACT questions 2 and 5; [Table 4](#T0004)). In AQ20 questionnaire the low physical activity group reported more breathlessness in questions 3 (breathlessness during gardening) (*p* = 0.002), 13 (breathlessness during housework) (*p* = 0.020) and 10 (difficulties in getting around the house due to chest problems) (*p* = 0.028) (eTable 5).10.1080/20018525.2018.1533753-T0004Table 4.Asthma control and symptoms at follow-up. ≤240 min of physical activity/day\>240 min of physical activity/day*p*-value\*Uncontrolled asthma\*\*27 (36.5)32 (25.2)0.234ACT score at follow-up22 (17--24)22 (20--24)0.159ACT Q2 shortness of breath at least 3--6 times/week22 (29.7)16 (12.6)**0.005**ACT Q5 asthma somewhat controlled, poorly controlled, not at all controlled25 (33.8)25 (19.7)**0.029**[^5]

Association of daily physical activity, systemic and airway inflammatory parameters {#S0003-S2005}
-----------------------------------------------------------------------------------

Blood neutrophils, eosinophils, FeNO, IL-6, and hsCRP were measured. No differences were observed in any of these biomarkers of inflammation between the high and low activity groups (eTable 6).

Factors associated with lung function decline {#S0003-S2006}
---------------------------------------------

To assess whether lower physical activity remains statistically significant factor associated with more rapid lung function decline in patients with adult-onset asthma after adjusting for age, sex, smoking, BMI, atopy, and use of inhaled glucocorticoid, we carried out multiple linear regression analysis. Daily physical activity ≤240 min remained statistically significantly associated with more rapid decline in FEV~1~ in adjusted analysis. Other explanatory factors of faster lung function decline were sex (male), atopy, and a higher BMI. ([Table 5](#T0005)) During the building of this linear regression model other variables were tried but inclusion of these variables gave the best model.10.1080/20018525.2018.1533753-T0005Table 5.Association of explanatory factors with lung function decline from Max~0-2.5~ to follow-up in multiple linear regression.VariableEstimate (∆ml)95% Confidence Interval*p*-value(Constant)−22.39−69.16 to 24.390.346Physical activity over 240 min/day17.908.00 to 27.80**\<0.001**Sex (female)13.123.08 to 23.16**0.011**Age at follow-up−0.23−0.59 to 0.130.209BMI at follow-up−1.01−2.02 to −0.01**0.048**Not a daily ICS user at follow-up1.40−10.15 to 12.950.811Atopy−11.38−21.72 to −1.04**0.031**Ever smoker at follow-up−1.97−11.70 to 7.760.690[^6]

Discussion {#S0004}
==========

The aim of this study was to examine the significance of daily physical activity in adult-onset asthma. Our data indicates that higher daily physical activity is associated with slower decline in lung function even when adjusting for sex, age, BMI, atopy, medication, and smoking. High and low physical activity groups in this study had no difference in BMI, smoking, medication, interleukin-6, hs-CRP, IgE, blood neutrophil or eosinophil counts, FeNO levels, or the frequency of exercise. The fact that there was no difference in BMI was surprising since high BMI has been linked to low physical activity \[[26](#CIT0026)\]. The low cut-off point of 240 min could explain the absence of differences in inflammatory markers. Also, differences in dietary habits and energy expenditure can explain the absence of BMI difference. High physical activity group had a higher percentage of females, which suggests that females do more low intensity physical activities in this set up. There was no difference in biomarkers of systemic inflammation between the groups with lower and higher daily physical activity even though it has been shown that regular physical exercise can reduce systemic inflammation \[[27](#CIT0027)\]. The frequency of exercise was not associated with lung function decline in this study, which was expected since there were no significant differences in the frequency of exercise between the two groups of high and low levels of daily physical activity.

To our knowledge this study is the first to examine the association between daily physical activity and FEV~1~ decline in clinical asthma. Our finding is supported by a similar association recently reported between leisure time activity and lung function change in persons having self-reported asthma in a population based cohort of the Nord-Trøndelag Health Study \[[28](#CIT0028)\]. Our study has several strengths. All asthmatics were carefully diagnosed by a respiratory physician, and the diagnosis was verified with spirometry, serial peak flow measures, or measures of bronchial hyperreactivity. Most patients were treated with at least inhaled glucocorticoids between Max~0-2.5~ and follow-up. Smokers and patients with co-morbidities were not excluded making this a real life study. During 1999--2002 a considerable proportion of novel asthma diagnoses in the region were made at Seinäjoki Central Hospital and \>94% of the patients obtaining diagnosis of asthma in this hospital at the study period took part in the study \[[18](#CIT0018)\]. Therefore, this study population well represents a primary care population with asthma. However, patients with very mild or seasonal asthma may have been excluded since patients had to fill the strict lung function criteria \[[18](#CIT0018)\].

The cut-off point for high and low levels of daily physical activity in this study was chosen at 240 min of physical activity per day. The cut-off point divided the cohort into the lowest one third against the two highest thirds. The patients were made well aware of what the question meant so that all misunderstandings could be minimized. Patients in this study had a median of 360 min of daily physical activity, which is similar to levels measured by accelerometers in patients with chronic diseases (range 308--395 min) \[[29](#CIT0029)--[31](#CIT0031)\]. The cut-off point of 240 min of physical activity is a relatively low level considering that even older care home residents in the UK \[[32](#CIT0032)\] and aged (73--98 year-olds) Icelandic people \[[33](#CIT0033)\] accumulated 122--190 min of daily physical activity. The cut-off point was intentionally set at this relatively low level to allow examinations of the effects of very low amounts of physical activity.

The most significant limitation of this study is the absence of spirometric post-bronchodilator values at Max~0-2.5~. This is due to the fact that the patients were treated according to the Finnish asthma guidelines where systematic recording of post-bronchodilatory values was not recommended at that time. Even though the patients' estimates on their physical activity are close to measured values on similar cohorts, it would have been optimal to record daily physical activity using accelerometers. In addition, physical activity was assessed only at follow-up visit. However, it has been shown that most of our health related habits are formed during childhood or early adulthood and decline slowly or remain constant during adulthood. Significant changes in health related habits are unlikely to happen without a comprehensive lifestyle intervention \[[34](#CIT0034),[35](#CIT0035)\]. Therefore, it can be assumed that the high physical activity group had higher activity levels also at diagnosis.

Similar findings to our study have been previously obtained in patients with COPD and in general population \[[14](#CIT0014),[16](#CIT0016)\]. During an 11-year follow-up in patients with COPD, low physical activity group had a faster decline in lung function (−4.8 ml/year faster drop of FEV~1~, −7.7 ml/year faster drop of FVC) when compared to high physical activity group \[[14](#CIT0014)\]. Slower FEV~1~ decline with higher physical activity has been detected on general population also \[[16](#CIT0016)\]. In our study FEV~1~ declined 17.4 ml/year faster, and FVC declined 14.3 ml/year faster in the low activity group. Sex (male), high frequency of disease exacerbations, old age, absence of glucocorticoid treatment, and smoking have been found to accelerate FEV~1~ decline in asthmatics \[[9](#CIT0009),[36](#CIT0036),[37](#CIT0037)\]. After adjusting for these factors with multiple linear regression analysis, the association of physical activity with FEV~1~ decline remained significant. Exacerbations were not included in the linear regression, but there was no difference in the proportion of those patients receiving oral corticosteroid treatment during the follow-up period between the physical activity groups suggesting that there was no difference in exacerbations.

The findings are clinically significant, since remission rate in adult onset asthma is low \[[7](#CIT0007)\] and most patients suffer from asthma for decades. The linearity of the effect of physical activity on lung function remains unclear. We found one daily physical activity intervention study in pediatric patients with asthma \[[38](#CIT0038)\], and no change in FEV~1~ was registered during a one-week follow-up. Also, in a recent cross-sectional study \[[39](#CIT0039)\] daily physical activity had no effect on spirometric values of healthy adolescents. In patients with childhood-onset asthma there is a positive association between physical activity and lung function during a 3 week period \[[40](#CIT0040)\], but this could be due to several acute bronchodilations or patients unconsciously adjusting their daily activity according to their lung function earlier that day. In light of this evidence it seems likely that daily physical activity does not cause long term improvements in FEV~1~, but that it slows down FEV~1~ decline. However, as the data on physical activity was collected at follow-up visit, the relation between lung function decline and physical activity level may also reflect that those with more rapid lung function decline are prone to decrease their level of physical activity.

Conclusion {#S0005}
==========

This study highlights the importance of active lifestyle and the perils of sedentary habits. Modern physical activity guidelines focus on higher intensity activities, but it would be important to include low intensity activities to these guidelines for more holistic approach. More studies with a precise analysis of the activity intensity are needed to further explore the effect of physical activity on patients with asthma.
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###### Supplemental Material

[^1]: **This study is registered at** [**www.ClinicalTrials.gov**](http://www.ClinicalTrials.gov) **with identifier number NCT02733016.**

[^2]: \*Statistical significances were evaluated using Mann-Whitney test, independent samples t-test or Chi-square test, respectively. Results are displayed as median (interquartile range), mean (SD), or *n* (%). BMI: body mass index; FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity; COPD: chronic obstructive pulmonary disease; ICS: inhaled corticosteroid; LABA: long acting beta-adrenoceptor agonist.

[^3]: \*Statistical significances were evaluated using Mann-Whitney test or independent samples t-test. Results are displayed as median (interquartile range) or mean (SD).FVC: forced vital capacity; BD: bronchodilator; FEV1: forced expiratory volume in 1 s.

[^4]: \*Statistical significances were evaluated using Mann-Whitney test or independent samples t-test. Results are displayed as median (interquartile range) or mean (SD). FVC: forced vital capacity, BD: bronchodilator, FEV1: forced expiratory volume in 1 s.

[^5]: \*Statistical significances were evaluated using Chi-square test or Mann-Whitney test. Results are displayed as *n* (%) or median (interquartile range). ACT: asthma control test.

    \*\*As assessed according to GINA 2010 as previously described \[18\].

[^6]: *n = 173 (outliers: n = 7, missing data: n = 21), BMI: body mass index, ICS: inhaled corticosteroid.*
